by Crestone, Inc. | Jul 16, 2025 | Events
Crestone had the opportunity to showcase its innovative research at two prestigious conferences: the 9th AMR Conference in Basel, Switzerland, and ICDS 2024 in Bled, Slovenia. These presentations highlighted CRS3123, a narrow spectrum agent designed for the treatment...
by Crestone, Inc. | Jul 11, 2025 | Events
Crestone made a significant impact at the ASM Microbe 2025 conference in Los Angeles by presenting groundbreaking research on microbiome analysis. Their presentation, delivered by Dr. Oren Gordon, focused on a Phase 2 clinical trial that compared CRS3123, one of their...
by Crestone, Inc. | Jul 11, 2025 | Events
Crestone showcased their innovative work at the ESCMID Global conference in Vienna on April 15, 2025. Delivered by Dr. Jon Brus, the highlight of their presentation was CRS3123, a groundbreaking treatment demonstrating high cure rates and low recurrence in addressing...
by Crestone, Inc. | Sep 5, 2024 | Press Releases
Primary endpoint met with high rates of clinical cure at day 12 Very low rates of recurrence observed with CRS3123 CRS3123 was generally safe and well tolerated NIAID exercises $4.5 million option to fund phase 2 supporting studies BOULDER, CO, September 5, 2024...
by Crestone, Inc. | Feb 24, 2023 | Information
We know it can be difficult when germs like bacteria and fungi learn to fight back against the medicines designed to keep them in check. This is called antimicrobial resistance, and it’s a natural process that can unfortunately make some infections very hard...
